AbbVie (NYSE:ABBV) Stock Price Down 1.3% – Here’s What Happened

by · The Markets Daily

AbbVie Inc. (NYSE:ABBV – Get Free Report) shares traded down 1.3% during trading on Monday . The stock traded as low as $223.98 and last traded at $224.82. 5,207,819 shares changed hands during mid-day trading, a decline of 19% from the average session volume of 6,391,651 shares. The stock had previously closed at $227.70.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. UBS Group boosted their price objective on AbbVie from $195.00 to $220.00 and gave the company a “neutral” rating in a research report on Friday, November 7th. Guggenheim boosted their price target on shares of AbbVie from $227.00 to $242.00 and gave the stock a “buy” rating in a report on Monday, October 20th. HSBC set a $225.00 price objective on shares of AbbVie in a research report on Thursday, October 2nd. Wells Fargo & Company increased their price objective on shares of AbbVie from $240.00 to $260.00 and gave the company an “overweight” rating in a report on Friday, September 12th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a research note on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $241.85.

View Our Latest Report on AbbVie

AbbVie Stock Performance

The company has a market cap of $397.34 billion, a price-to-earnings ratio of 107.06, a PEG ratio of 1.42 and a beta of 0.50. The firm’s 50 day simple moving average is $227.71 and its 200-day simple moving average is $207.01. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.61 and a current ratio of 0.74.

AbbVie (NYSE:ABBV – Get Free Report) last posted its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, topping the consensus estimate of $1.77 by $0.09. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The firm had revenue of $15.78 billion for the quarter, compared to the consensus estimate of $15.58 billion. During the same period last year, the firm posted $3.00 earnings per share. The company’s revenue for the quarter was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, sell-side analysts predict that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be given a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.1%. This is a boost from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. AbbVie’s dividend payout ratio (DPR) is currently 524.24%.

Hedge Funds Weigh In On AbbVie

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Marshall & Sullivan Inc. WA purchased a new stake in shares of AbbVie in the second quarter valued at about $25,000. Evolution Wealth Management Inc. purchased a new stake in shares of AbbVie in the 2nd quarter valued at approximately $26,000. Chelsea Counsel Co. purchased a new stake in shares of AbbVie in the 3rd quarter valued at approximately $26,000. TD Capital Management LLC increased its holdings in shares of AbbVie by 82.9% during the 1st quarter. TD Capital Management LLC now owns 128 shares of the company’s stock worth $27,000 after buying an additional 58 shares during the last quarter. Finally, Spurstone Advisory Services LLC purchased a new stake in shares of AbbVie during the 2nd quarter valued at approximately $28,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Company Profile

(Get Free Report)

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

Read More